Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanifibranor - Inventiva Pharma

Next Previous
Drug Profile

Lanifibranor - Inventiva Pharma

Alternative Names: IVA-337

Latest Information Update: 07 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inventiva Pharma
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antineoplastics; Benzothiazoles; Butyric acids; Halogenated hydrocarbons; Hepatoprotectants; Indoles; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; PPAR gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Fibrosis; Non-alcoholic steatohepatitis
  • Phase II Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • No development reported Bladder cancer; Liver cirrhosis
  • Discontinued Systemic scleroderma

Most Recent Events

  • 02 Sep 2026 Inventia Pharma expects launch of Lanifibranor in USA in 2028
  • 02 Sep 2026 Inventia Pharma anticipates regulatory submission of Lanifibranor in the first half of 2027
  • 01 Sep 2026 Inventiva announces intention to launch lanifibranor in USA for Non-alcoholic fatty liver disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top